Compare Agilent Technologies Inc (A) vs Revvity Inc (RVTY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs Revvity Inc — how do they compare? Agilent Technologies Inc trades at $129 (market cap $37.04B), while Revvity Inc trades at $109.1 (market cap $12.50B). The key difference: Agilent Technologies Inc is far larger — about 3× Revvity Inc's market cap, and Agilent Technologies Inc pays the higher dividend (0.78%). Which is the better fit depends on your goals.
| A | RVTY | |
|---|---|---|
Market Cap | $37.04B | $12.50B |
Sector | Health | Technology |
52-Week High | $157.20 | $117.75 |
52-Week Low | $110.24 | $82.26 |
Enterprise Value | $38.59B | $14.99B |
Dividend Yield | 0.78% | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Revvity (RVTY) trades at $112.95, down 0.71% on the day, with strong technical momentum indicated by bullish moving averages. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Recent AI integration announcements with Anthropic's Claude platform highlight ongoing innovation in scientific R&D workflows.
The stock presents a mixed outlook with strong earnings performance and AI-driven growth initiatives offset by elevated valuation multiples. Key risks include margin pressure and competitive threats in the life sciences sector. Analyst consensus leans bullish with a $109.38 price target, though current price exceeds this level.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
